

1/19

LCMS ANALYSIS OF RECOMBINANT PEPTIDE VARIANTS





FIG. 1A

2/19




FIG. 1B

3/19




FIG. 1C

4/19

CHEMICALLY SYNTHESIZED PEPTIDES IN THE INTESTINAL GC-C RECEPTOR ACTIVITY ASSAY




FIG. 2

5/19

SEQ ID NO: 26 vs ZELNORM® IN AN ACUTE MOUSE  
GASTROINTESTINAL TRANSIT MODEL (GIT)




FIG. 3A

6/19






FIG. 3B


7/19



8/19



9/19



10/19




FIG. 5A

11/19




FIG. 5B

12/19

RECOMBINANTLY GENERATED SEQ ID NO: 28 AND SEQ IN NO: 26 IN MOUSE  
INTESTINAL SECRETION MODEL




FIG. 6A

13/19

CHEMICALLY SYNTHESIZED PEPTIDES IN MOUSE INTESTINAL SECRETION MODEL





FIG. 6B

14/19

EFFECT OF SEQ ID NO: 31 IN RAT TNBS  
COLORECTAL DISTENSION ASSAY



\*p<0.05 as compared to "vehicle" value

FIG. 7

15/19




FIG. 8A

16/19

VISCERAL ANTINOCICEPTIVE EFFECTS OF  
SEQ ID NO: 31 IN A MOUSE WRITHING ASSAY




FIG. 8B  
SEQ ID NO: 31

17/19

COMPETITIVE RADIOLIGAND BINDING  
OF SEQ ID NO: 31





FIG. 9

18/19

MINIMUM SYSTEMIC ABSORPTION OF SEQ ID NO: 31  
(BASED ON ELISA)




\* Limit of detection 0.061  $\mu\text{g/ml}$   
Dosing at 10 mg/kg

FIG. 10A

19/19

MINIMUM SYSTEMIC ABSORPTION OF  
SEQ ID NO: 31 (BASED ON LC/MS)



\* Limit of detection 0.0063  $\mu\text{g}/\text{ml}$  (0.6 nM)

\* Dosing at 10 mg/kg

FIG 10B